Single and Multiple Dose Study of MK-1708 in Healthy Japanese Participants

JRCT ID: jRCT2071240035

Registered date:20/07/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Alzheimer's disease, Amyotrophic lateral sclerosis
• Date of first enrollment: 24/08/2024
• Target sample size: 64
• Study type: Interventional
• Intervention(s): In Part 1, a single oral dose of MK-1708 1.8, 5, 10, 20 mg, or placebo will be administered. In Part 2, multiple oral doses of MK-1708 10 mg or less or placebo will be administered once daily for 12 days.

Outcome(s)

• Primary Outcome: Safety (Adverse Events, Discontinuations due to Adverse Events)
• Secondary Outcome: Pharmacokinetics (Evaluation of plasma pharmacokinetics, comparison of plasma pharmacokinetics among CYP2C19 phenotypes)

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: <= 55age old
• Gender: Both
• Include criteria: Healthy male participants and female participants of nonchildbearing potential between the ages of 18 and 55 years
• Exclude criteria: Has a history of clinically significant abnormalities or diseases

Related Information

• Primary Sponsor: Yoshitsugu Hiroyuki
• Secondary ID(s): NA